Identification of candidate miRNAs in early-onset and late-onset prostate cancer by network analysis

被引:0
作者
Rafael Parra-Medina
Liliana López-Kleine
Sandra Ramírez-Clavijo
César Payán-Gómez
机构
[1] Universidad del Rosario,Department of Biology, Faculty of Natural Sciences
[2] Fundación Universitaria de Ciencias de la Salud,Department of Pathology, Research Institute
[3] Instituto Nacional de Cancerología,Pathology Deparment
[4] Universidad Nacional de Colombia,Department of Statistics, Faculty of Science
来源
Scientific Reports | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The incidence of patients under 55 years old diagnosed with Prostate Cancer (EO-PCa) has increased during recent years. The molecular biology of PCa cancer in this group of patients remains unclear. Here, we applied weighted gene coexpression network analysis of the expression of miRNAs from 24 EO-PCa patients (38–45 years) and 25 late-onset PCa patients (LO-PCa, 71–74 years) to identify key miRNAs in EO-PCa patients. In total, 69 differentially expressed miRNAs were identified. Specifically, 26 and 14 miRNAs were exclusively deregulated in young and elderly patients, respectively, and 29 miRNAs were shared. We identified 20 hub miRNAs for the network built for EO-PCa. Six of these hub miRNAs exhibited prognostic significance in relapse‐free or overall survival. Additionally, two of the hub miRNAs were coexpressed with mRNAs of genes previously identified as deregulated in EO-PCa and in the most aggressive forms of PCa in African-American patients compared with Caucasian patients. These genes are involved in activation of immune response pathways, increased rates of metastasis and poor prognosis in PCa patients. In conclusion, our analysis identified miRNAs that are potentially important in the molecular pathology of EO-PCa. These genes may serve as biomarkers in EO-PCa and as possible therapeutic targets.
引用
收藏
相关论文
共 164 条
[41]  
Pashaei E(2015)Glycogen synthase kinase-3: A potential preventive target for prostate cancer management Urol. Oncol. Semin. Orig. Investig. 33 456-1186
[42]  
Pashaei E(2012)p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3 Cell Cycle 11 4579-1327
[43]  
Ahmady M(2016)Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome Oncotarget 7 11056-329
[44]  
Ozen M(2019)MicroRNA-488-3p inhibits proliferation and induces apoptosis by targeting ZBTB2 in esophageal squamous cell carcinoma J. Cell. Biochem. 120 18702-258
[45]  
Aydin N(2012)Role of transcriptional corepressor CtBP1 in prostate cancer progression Neoplasia 14 905-IN8-56
[46]  
Valera VA(2008)Role of platelet-derived growth factors in physiology and medicine Genes Dev. 22 1276-189
[47]  
Parra-Medina R(1996)Platelet-derived growth factor A and B chains and the α and β receptors in prostatic intraepithelial neoplasia Prostate 29 282-210
[48]  
Walter BA(2012)PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer Am. J. Pathol. 180 1017-5649
[49]  
Pinto P(2017)High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence Sci. Rep. 7 43378-248
[50]  
Merino MJ(2017)Cdk2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage Sci. Rep. 7 13429-233